Four WIN compounds with anti-picornavirus activities were tested for their ability to stabilize human rhinovirus serotype 2 (HRV-2) against low pH-induced conformational changes in vitro, as determined by specific immunoprecipitation. These results were compared to the minimal inhibitory concentration (MIC) as measured in a plaque reduction assay. A direct relationship was observed between the concentration of the compound that prevented the low pH-induced conformational changes and the MIC, indicating that stabilization is an important element in the mode of action of these drugs against HRV-2.
The capsid of human rhinoviruses (HRVs), members of the picornavirus family, undergoes conformational changes during endocytosis. These structural alterations of the capsid are thought to be a prerequisite for uncoating (Lonberg-Holm & Whiteley, 1976; Neubauer et al., 1987) . This change of structure has also been observed in vitro upon incubation of virions at low pH or at 56 °C (Korant et al., 1972; Kowalski et al., 1989) . Recently, several antiviral compounds have been synthesized which were shown to bind to a hydrophobic pocket in the viral capsid (Smith et al., 1986) . For the members of the rhinovirus major receptor group, the effect of these compounds has been attributed to a displacement of the canyon floor, the putative receptor binding site, thus disturbing receptor recognition Rossmann et al., 1985; . For the members of the rhinovirus minor receptor group, these compounds are believed to stabilize the capsid, probably by decreasing the flexibility of the polypeptide chains (Kim et al., 1989; Pevear et al., 1989) . The activity of various WIN and other antiviral compounds towards several picornaviruses has been determined in vivo by plaque reduction assays Woods et al., 1989) .
In the present study we examined the effect of the antiviral compounds IV (disoxaril), I(S), VI and VIII (for the structure of the compounds see Pevear et al., 1989) on conformational changes of HRV-2, a member of the minor receptor group. Changes induced by incubation at low pH in vitro were monitored using monoclonal antibody (MAb) 2G2. This MAb has been shown to recognize an antigenic determinant that appears upon incubation of HRV-2 at a pH of around 5-5 but which is absent on native virions (Neubauer et al., 1987) . The compounds were selected to cover a wide range of minimal inhibitory concentrations (MICs) against HRV-2.
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[3SS]methionine-labelled HRV-2 (Neubauer et al., 1987) was preincubated with or without the antiviral compounds for 60 min at 20 °C in 300 rtl phosphate-buffered saline. The pH was adjusted with 1 M-sodium acetate buffer to the values shown in Fig. 1 , and the incubation was continued for an additional 30 min. An appropriate volume of 0.5 M-Tris was then added to readjust the pH to 7.4.
Immunoprecipitation of virions in the altered conformation was done essentially as described (Neubauer et al., 1987) . The pellet was washed two times with RIPA buffer, dissolved in Protosol (New England Nuclear) and counted in a scintillation counter; radioactivity in the supernatant was also determined. Counts in the pellet plus counts in the supernatant were taken as 100K for each determination.
As can be seen in Fig. 1 , the amount of precipitated radioactive viral material increased substantially between pH 5.8 and pH 5.6 in the absence of any antiviral compound. Preincubation of virus with 40 ~tg/ml of compound IV, I(S) or VI, however, prevented the capsid from changing its conformation even at pH 5.5. Destabilization was found to occur in the presence of compounds in a pH range between pH 5-4 and 5.2. In the case of compound VIII the conformational change appeared at a pH of around 5.6, which is only marginally different from the value observed 0000-9870 © 1991 SGM without any compound. This is consistent with its lack of antiviral activity in a plaque reduction assay (see legend to Fig. 2) . The reason why MAb 2G2 does not precipitate all the radioactive virus upon low pH treatment is not clear. It probably indicates that a fraction of the virus assumes a conformation upon denaturation which is not recognized by MAb 2G2.
It thus becomes apparent that, with the exception of compound VIII, all compounds tested stabilized the virion down to a similar pH value at this concentration. Whereas the viral capsid became immunoprecipitable with MAb 2G2 at pH values between 5-8 and 5.6 in the control, a pH of below 5.3 was needed when compounds I(S), IV or VI were present; compound VIII did not stabilize the virion appreciably. As these pH values are in the same range as those which are observed in endosomal compartments, it is likely that only a small increase in pH stability is sufficient for the viral capsid to be blocked in uncoating at the appropriate site (Helenius et al., 1980; Davoust et al., 1987) . This is consistent with the observation that lysosomotropic agents, which increase the pH in endosomes and lysosomes, also cause inhibition of conformational change and prevent infection (Madshus et al., 1984a, b; Neubauer et al., 1987) .
In order to determine whether a relationship existed between the concentration of a compound needed for pH stabilization and that required for inhibition of plaque formation, dose-response curves were determined. A pH Points are the mean of at least three independent determinations.O, Compound VIII; O, compound VI; I, compound IV; V, compound I(S). ACs0 ~g/ml) values are shown; MIC values were 0.03 p.g/ml, 0.34 lxg/ml, 2-46 ~tg/ml and > 12.5 lag/ml for compounds I(S), VI, IV and VIII, respectively, as determined by plaque reduction assay.
of 5-4 was chosen for the incubations at different concentrations of compounds I(S), IV, VI and VIII. The curves (Fig. 2) show that the concentrations required for stabilization at pH 5.4 differed in each case. The MICs of the individual WIN compounds when acting against HRV-2, presented in Fig. 2 , were obtained essentially as described . The compound with the lowest MIC, I(S), also exerts its in vitro effect at the lowest concentration, whereas compound IV needs a twofold greater concentration to produce the same effect (note the semilogarithmic scale in Fig. 2) . Compound VIII had no stabilizing effect at pH 5.4 (see Fig. 1 ), consistent with its lack of activity in the plaque reduction assay. From these data an estimate of the median antigenic conversion (ACso) was calculated as the concentration of a given compound that blocks 50~ antigenic conversion at pH 5.4 when compared to the control in the absence of the compound. The corresponding concentrations were, however, determined with 45 precipitated material because the maximum value obtained was 70~ and the minimum value 20~ (Fig. 2) . As seen in Fig. 2 and 3 , the different efficiencies of the WIN compounds in stabilizing HRV-2, as revealed by the dose-response curves in vitro, strongly correlate with the MICs (r z = 0-858). This concentration dependence presumably reflects differences in the affinities of the 
